Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Osteologix's NB S101 meets osteoporosis endpoint

OLGX said NB S101 (formerly NBS-101) met the primary endpoint of a significant reduction

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE